| NKCx Histopathological outcome* within 12 months after cervix cytology in 2024 |
| 571 Dalarna |
| Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benign sample | 50 | 5.2% | 39 | 4.1% | 15 | 1.6% | . | . | . | . | . | . | 854 | 89.1% | 958 | 100.0% |
| ASCUS | 25 | 14.5% | 65 | 37.6% | 37 | 21.4% | . | . | . | . | 1 | 0.6% | 45 | 26.0% | 173 | 100.0% |
| LSIL | 17 | 16.2% | 35 | 33.3% | 29 | 27.6% | . | . | . | . | . | . | 24 | 22.9% | 105 | 100.0% |
| Atypical glandular cells/AGC | . | . | 1 | 50.0% | . | . | 1 | 50.0% | . | . | . | . | . | . | 2 | 100.0% |
| ASC-H | . | . | 3 | 17.6% | 9 | 52.9% | 2 | 11.8% | 1 | 5.9% | . | . | 2 | 11.8% | 17 | 100.0% |
| HSIL | 1 | 10.0% | . | . | 8 | 80.0% | . | . | . | . | 1 | 10.0% | . | . | 10 | 100.0% |
| Squamous cell cancer | . | . | . | . | 1 | 100.0% | . | . | . | . | . | . | . | . | 1 | 100.0% |
| Totalt | 93 | 7.3% | 143 | 11.3% | 99 | 7.8% | 3 | 0.2% | 1 | 0.1% | 2 | 0.2% | 925 | 73.1% | 1266 | 100.0% |
| NOTE: Histopathological outcome from T83x taken into account. |
| This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
| * Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
| The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
| Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
| Snomed codes in the category Cancer: |
|---|
| M81403 |